About SCRI
SCRI is one of the world's leading oncology research
organizations conducting community-based clinical trials.
Focused on advancing therapies for patients over the last
three decades, SCRI is a leader in drug development.
In 2022, SCRI formed a joint venture with former US
Oncology Research to expand clinical trial access across the
country. It has conducted more than 750 first-in-human clinical
trials since its inception and contributed to pivotal research
that has led to the majority of new cancer therapies approved
by the FDA today. SCRI's research network brings together
more than 1,300 physicians who are actively enrolling
patients into clinical trials at more than 250 locations in
24 states across the U.S.
